Clinical advances in multiple sclerosis and amyotrophic lateral sclerosis treatment: A review
DOI:
https://doi.org/10.36105/psrua.2021v1n2.06Keywords:
clinical advances, reatment and multiple/amyotrophic lateral sclerosis, sclerosisAbstract
Neurodegenerative diseases are clinical manifestations that depend on the anatomy and function of the affected areas. Amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) are some of these diseases, but they are also autoimmune and their etiology makes treatments limited and of little therapeutic efficacy. Currently, some clinical research advances can be pillars for the development of new treatments for these diseases. Therefore, the objective of this review is to describe the latest clinical advances in ALS and MS as well as their results in clinical recovery in randomized clinical trials, meta-analyzes, and full-text systematic reviews conducted in humans and rats, published in English and Spanish in the last 5 years, using PubMed, SciELO, and Cochrane. For clinical trials to be included, they had to provide a detailed breakdown of randomization methods, diagnostic criteria, intervention details, and efficacy evaluation. The results show that, so far, available medications, like riluzole and edaravone for ALS and fingolimod, dimethyl fumarate, and IFN β-1b for MS, only prolong the life of the patient. Among these drugs are also glutamate neurotransmitter antagonists, immunomodulators and even antioxidants; each of them showed significant improvement in the reviewed trials. Similarly, other non-pharmaceutical treatments, as the 600-mg dose of curcumin in the diet for ALS, showed improvement of the patients’ conditions. Regarding MS, more studies should be carried out on autotransplantation with adiposederived mesenchymal stem cells (AdMSCs) to investigate the potential therapeutic benefit of this technique in phases prior to secondary-progressive (SPMS).
Downloads
PLUMX metrics
References
2. Diamond B, and Lipsky P. Capítulo 348: Autoinmunidad y enfermedades autoinmunitarias. En Jameson L, Fauci A, Kasper D, Hauser S, Longo D, and Loscalzo J. Harrison. Principios de Medicina Interna, 20e. Ciudad de México, México; Editorial McGraw Hill Education; 2018.
3. Roberson, E. Capítulo 18: Tratamiento de los trastornos degenerativos del sistema nervioso central. En Brunton L, Chabner B, and Knollmann B. Goodman & Gilman: Las Bases Farmacológicas De La Terapéutica, 13e. Ciudad de México, México; Editorial. McGraw Hill Education; 2019.
4. Bucchia M, Ramirez A, Parente V, Magri F, Dametti S, Corti S, et al. Therapeutic Development in Amyotrophic Lateral Sclerosis. Clinical Therapeutics. 2015;37:3. https://doi.org/10.1016/j.clinthera.2014.12.020
5. Ropper A, Samuels M, Klein J, Prasad S. CAPÍTULO 38: Enfermedades degenerativas del sistema nervioso. En Enfermedades degenerativas del sistema nervioso. Adams y Victor. Principios de neurología, 11e. España: Editorial McGraw Hill Education; 2019.
6. Chico L, Caldarazzo E, Bisordi C, Lo Gerfo A, Petrozzi L, Petrucci A, et al. Amyotrophic Lateral Sclerosis and Oxidative Stress: A Double-Blind Therapeutic Trial After Curcumin Supplementation. CNS Neurol Disord Drug Targets. 2018;17(10):767-779. https://doi.org/10.2174/1871527317666180720162029
7. Capítulo 4: Transducción de señales en el cerebro. En Nestler E, Hyman S, Holtzman D, y Malenka R. Neurofarmacología molecular. Fundamentos de neurociencia clínica, 3e. México: Editorial McGraw Hill Education; 2018.
8. Wills A, Garry J, Hubbard J, Mezoian T, Breen C, Ortiz-Miller C, et al. Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS. BMC Neurol. 2019;19:104. https://doi.org/10.1186/s12883-019-1330-6
9. Mayo Foundation for Medical Education and Research. Esclerosis Múltiple. [Internet]. Mayo Clinic. 2017 [citado 03 Junio 2020]. Disponible en: https://www.mayoclinic.org/es-es/diseases-conditions/multiple-sclerosis/symptoms-causes/syc-20350269
10. Carretero J, Bowakim W, and Acebes J. Actualización: esclerosis múltiple. MEDIFAM 2001;11:516-529. Disponible en: http://scielo.isciii.es/pdf/medif/v11n9/colabora.pdf
11. Domínguez R, Morales M, Rossiere N, Olan R, and Gutiérrez J. Esclerosis múltiple: revisión de la literatura médica. Revista de la Facultad de Medicina de la UNAM. 2012;55:5. Disponible en: https://www.medigraphic.com/pdfs/facmed/un-2012/un125e.pdf
12. Simon R, Greenberg D, and Aminoff M. Capítulo 5: Deficiencias motoras. En Neurología clínica, 7e. 2010 [citado 10 Junio 2020]. McGRAW HILL/INTERAMERICANA EDITORES, S.A. de C.V. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=1505§ionid=97683699#105227437
13. Punt J, Stranford S, Jones P, and Owen J. CAPÍTULO 10: Activación, diferenciación y memoria de células T. En KUBY. Inmunología, 8e. 2014 [citado 10 Junio 2020]. McGRAW HILL/INTERAMERICANA EDITORES, S.A. de C.V. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=2951§ionid=248864754
14. Berkowitz, A. Neurología clínica y neuroanatomía. Un enfoque basado en la localización: Enfermedades desmielinizantes del sistema nervioso central. En Neurología clínica, 7e. 2010 [citado 10 Junio 2020]. McGRAW HILL/INTERAMERICANA EDITORES, S.A. de C.V. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=1505§ionid=97683699#105227437
15. Hart FM, Bainbridge J. Current and Emerging Treatment of Multiple Sclerosis. Am J Manag Care. 2016;22(6):159-70. Disponible en: https://www.ajmc.com/view/cost-effectiveness-multiple-sclerosis-current-emerging-treatment
16. McLaughlin L, Clarke L, Khalilidehkordi E, Butzkueven H, Taylor B, and Broadley S. Vitamin D for the treatment of multiple sclerosis: a meta-analysis. J Neurol. 2018; 265(12):2893-2905. https://doi.org/10.1007/s00415-018-9074-6
17. Payne C, Wiffen P and Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness.Cochrane Database Syst Rev. 2017; 4. Art CD008427. https://doi.org/10.1002/14651858.CD008427.pub3
18. Marrie R, Reingold S, Cohen J, Stuve O, Trojano M, Sorensen P, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Mult Scler. 2015;21(3):305–317. https://doi.org/10.1177/1352458514564487
19. Prosperini L, Piattella M, Giannì C and Pantano P. Functional and Structural Brain Plasticity Enhanced by Motor and Cognitive Rehabilitation in Multiple Sclerosis. Neural Plast. 2015. Art 481574. https://doi.org/10.1155/2015/481574
20. Diaz, G. M., Hupperts, R., Fraussen, J., & Somers, V. Dimethyl fumarate treatment in multiple sclerosis: Recent advances in clinical and immunological studies. Autoimmunity Reviews. 2018; 17: 12. Páginas 1240-1250. https://doi.org/10.1016/j.autrev.2018.07.001
21. Comi G, Patti F, Rocca M, Mattioli F, Amato M, Gallo P et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). J Neurol. 2017; 264: 12. Páginas 2436–2449. https://doi.org/10.1007/s00415-017-8642-5.
22. Fernández O, Izquierdo G, Fernández V, Leyva L, Reyes V, Guerrero M, et al. (2018) Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study. PLOS ONE. 2018; 13: 5. https://doi.org/10.1371/journal.pone.0195891
23. Schreiber, K., Magyari, M., Sellebjerg, F., Iversen, P., Garde, E., Madsen, C. G., … Soelberg Sorensen, P. High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal, 2017; 23: 5. Páginas 675–685. https://doi.org/10.1177/1352458516661048
24. Bitarafan S, Saboor-Yaraghi A, Sahraian MA, et al. Impact of Vitamin A Supplementation on Disease Progression in Patients with Multiple Sclerosis. Arch Iran Med. 2015; 18:7. Páginas 435-440.
25. Babaesfahani A, Bajaj T. Glatiramer. [Updated 2020 Jun 2]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK541007/
26. Meca-Lallana JE, Hernández-Clares R, Carreón-Guarnizo E. Spasticity in multiple sclerosis and role of glatiramer acetate treatment. Brain Behav. 2015; 5: 9. https://doi.org/10.1002/brb3.367
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Marquelle Zerecero-Morcksharpe, Elisa García-Vences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All the intellectual content found in this publication is licensed to the consumer public under the figure of Creative Commons©, unless the author of said content has agreed otherwise or limited said faculty to "Proceedings of Scientific Research Universidad Anáhuac. Multidisciplinary Journal of Healthcare©" or "Universidad Anáhuac Mexico©" in writing and expressly.
Proceedings of Scientific Research Universidad Anáhuac. Multidisciplinary Journal of Healthcare is distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The author retains the economic rights without restrictions and guarantees the journal the right to be the first publication of the work. The author is free to publish his article in any other medium, such as an institutional repository.
